Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 238 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: S. aureus Clear all

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Methicillin-resistant Staphylococcus Aureus
Interventions: Chlorhexidine bath and nasal mupirocin; Drug
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 13 Years and older
Enrollment: 74,256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 42
States / cities: Anchorage, Alaska • Thousand Oaks, California • Aurora, Colorado + 32 more

Conditions: Community-Acquired Staphylococcus Aureus
Interventions: Routine Measures Group, Bleach Bath Group (Bleach plus routine measures); Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Months to 18 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Staphylococcus Aureus, HIV Infections
Interventions: rifabutin plus trimethoprim sulfamethoxazole, placebo plus trimethoprim-sulfamethoxazole; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis, MRSA
Interventions: Rifampin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nosocomial Bacteremia, Nosocomial Fungemia, MRSA Colonization, MRSA Infection, VRE Colonization, VRE Infection
Interventions: Daily bathing with Chlorhexidine based product; Behavioral
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 5,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: Staphylococcus Aureus Bacteremia
Interventions: Ceftobiprole medocaril, Daptomycin; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more

Conditions: Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions: Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 15
States / cities: Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more

Conditions: Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions: Vancomycin, Daptomycin, Semi-Synthetic Penicillin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Azusa, California • Los Angeles, California • Torrance, California + 7 more

Conditions: Bone Infection, Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: AO Clinical Investigation and Publishing Documentation; Other
Eligibility: 18 Years to 130 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 5
States / cities: Columbia, Missouri • Rochester, New York • Danville, Pennsylvania + 1 more

Conditions: Staphylococcal Skin Infections, Abscesses, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions: 2% Mupirocin Ointment, 4% Chlorhexidine liquid soap, Hygiene protocol; Drug · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Months to 21 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Staphylococcus Aureus Bacteremia
Interventions: 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment, Placebo plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II, Placebo plus standard IV antibiotic treatment: Phase II; Biological · Other
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Columbus, Georgia • Charlotte, North Carolina

Conditions: HIV Infections, Staphylococcal Infections
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: San Diego, California • Bethesda, Maryland

Conditions: S. Aureus Transmission
Interventions: Treatment Bundle (as defined below); Other
Lead sponsor: Randy Loftus; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Staphylococcal Infections, Candidiasis
Interventions: NDV-3 investigational vaccine; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Open Reduction and Internal Fixation of Extremity Fractures
Interventions: Blood draws; Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Staphylococcus Aureus Bacteremia
Interventions: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 2,096 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more

Conditions: Staphylococcal Infections
Interventions: S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate; Biological
Lead sponsor: Nabi Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Staphylococcus Aureus Infection
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 6 Months to 100 Years
Enrollment: 1,342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Coralville, Iowa

Conditions: Bacteremia, Septicemia
Interventions: Not listed
Lead sponsor: Karius, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Decatur, Georgia + 5 more

Conditions: Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: Hospital Acquired MRSA, Community Acquired MRSA
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: CF-301, Placebo; Biological · Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more

Search by objective public record fields.

Chart Review of Outcome of Treatment for S. Aureus Bacteremia

Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)

Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children

Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis

The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

Clinical Priority Program-Bone Infection Registry

Staphylococcus Aureus Decolonization Study

Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

Improving Case Selection for Perioperative S. Aureus Transmission Surveillance to Reduce Surgical Site Infections

Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

Evaluation of Consistency of StaphVAX Manufacturing Lots

Livestock Contact and MRSA in Rural Areas

Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay

Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

Hospital Acquired and Community Acquired MRSA in GI Lab

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia